ClinicalTrials.gg
Not yet recruitingNCT07847944NEUROLEAUpdated Sep 29, 2026

Neuroprotective Effects of Oleanolic Acid and Erythrodiol in Prodromal Alzheimer's Disease

An interventional study of Oleanolic acid-enriched olive oil and Pomace olive oil in Alzheimer s Disease and Prodromal Alzheimer's Disease, sponsored by Spanish National Research Council. Not yet recruiting at 1 site in Spain. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Spanish National Research Council · Not applicable, Interventional, and Prevention

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.

Planned enrollment
162nd of 240
120 · median 258
Started
2027
the only one that year
No phase
66 of 279
17 open now
Primary completion
2028-10
later than 59 of 79 live
Registered
278th of 279
by date

Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 162nd largest by planned enrollment of the 240 interventional ones that give a count, is the only one that started in 2027, is one of 66 with no phase, reaches primary completion later than 59 of the 79 other live ones, and was the 278th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Alzheimer Disease with a site in Spain, or all of them as a file.
02

Study summary

Alzheimer's disease begins many years before memory problems become obvious. People in the early ("prodromal") stage have memory complaints but are still independent in daily life. At present there is no treatment that prevents this stage from progressing to dementia.

Olive oil contains two natural compounds, oleanolic acid and erythrodiol. Earlier work by this research team suggests that these compounds may reduce inflammation and oxidative stress and may improve the way the body handles sugars and fats, processes that are also altered in Alzheimer's disease.

This study will test whether consuming olive oils that contain these compounds delays the progression from prodromal Alzheimer's disease to dementia.

A total of 120 adults aged 50 to 80 years with prodromal Alzheimer's disease will take part at three public hospitals in southern Spain. Participants will be assigned by chance to one of three groups and will consume 55 mL per day of one of three oils for 12 months: olive oil enriched with oleanolic acid, pomace olive oil (which naturally contains both compounds), or a standard commercial olive oil with very low levels of these compounds. Neither the participants nor the staff assessing them will know which oil each person is receiving.

Participants will attend study visits at the start of the study and after 6 and 12 months. At these visits they will complete memory and thinking tests, a physical and nutritional assessment, and blood and urine tests.

Read the detailed description

NEUROLEA is a multicenter, randomized, double-blind, controlled dietary intervention trial coordinated by the Instituto de la Grasa (CSIC). Participants will be recruited at the Neurology Units of Hospital Universitario Virgen del Rocío, Hospital Universitario Reina Sofía and Hospital Universitario de Valme.

Study oils. High-purity crystalline oleanolic acid (>95%) will be obtained from olive leaves following a procedure developed by the research team (Spanish Patent ES2160553) and used to prepare an oleanolic acid-enriched olive oil (600 mg/kg) according to European Patent EP18382510. A commercial olive oil 0.4° will serve as the control oil, as it has the same fatty acid composition as the other oils but a very low content of minor bioactive components. Pomace olive oil, which naturally contains oleanolic acid and erythrodiol, will be purchased from local markets. Oil composition will be verified by gas chromatography and differential scanning calorimetry before the intervention begins.

Randomization and blinding. Allocation will follow computer-generated random numbers prepared by the trial coordinator. Participants, clinical and nutritional research staff, and the neuropsychologists scoring the cognitive assessments will be blinded to group assignment.

Sample size. Thirty-four participants per arm are required for 90% power to detect a 10% reduction in dementia incidence in the functional oil arms compared with a 25% incidence in the control arm over 12 months (alpha 0.05). Allowing for up to 15% attrition in a long-term dietary intervention, the target is 40 participants per arm (120 in total).

Intervention and follow-up. Participants will consume 55 mL/day of the assigned oil, preferably raw and distributed across the three main meals, for 12 months. Adherence will be assessed with the self-reported Haynes-Sackett compliance test and by return of empty bottles, methods previously used by this team in the PREDIABOLE and OLTRAD trials. Participants and their caregivers will receive general healthy-eating guidance throughout the study.

Assessments. Evaluations will be performed at baseline and after 6 and 12 months, and will include a comprehensive neuropsychological battery, clinical examination, anthropometry and body composition by bioimpedance, dietary intake and diet quality questionnaires, and fasting blood and urine sampling. Serum concentrations of oleanolic acid and erythrodiol will be measured by HPLC-MS to verify exposure.

Mechanistic analyses. Beyond the clinical endpoints, the trial will examine circulating markers of lipid and glucose metabolism, oxidative stress and inflammation, and advanced glycation end product metabolism, together with the expression of related genes in peripheral blood mononuclear cells. Blood-based markers of Alzheimer's disease pathology (p-tau 217, neurofilament light chain, glial fibrillary acidic protein, and the amyloid beta 42/40 ratio) will be quantified at baseline and 12 months.

Data will be managed in REDCap and stored in pseudonymized form in accordance with the General Data Protection Regulation.

03

Conditions studied

  • Alzheimer s Disease
  • Prodromal Alzheimer's Disease

Browse trials for

Keywords

  • Oleanolic acid
  • Erythrodiol
  • Triterpenes
  • Olive oil
  • Dietary intervention
  • Neuroprotection
  • Advanced glycation end products
  • Functional Foods
  • Oxidative stress
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Men and women aged 50 to 80 years Diagnosis of prodromal Alzheimer's disease, meeting all of the following: memory complaints corroborated by a reliable informant; (MMSE) total score between 22 and 30; Free and Cued Selective Reminding Test (FCSRT, picture version) total recall score of 46 or less; Clinical Dementia Rating Global Score (CDR-GS) of 0.5; functional independence in activities of daily living (Functional Activities Questionnaire total score of 8 or less); plasma p-tau 217 above 0.45 pg/mL measured by the Lumipulse method Ability and willingness to attend scheduled visits at the study center Adequate visual and auditory capacity to complete study evaluations Educational level sufficient to read and write Written

Exclusion criteria

Exclusion Criteria:

Absence of a reliable informant Evidence, based on medical history or clinical evaluation, of a neurological condition other than Alzheimer's disease that could account for the cognitive impairment , advanced or unstable systemic disease that may interfere with cognitive evaluation Severe psychiatric disorders, including schizophrenia, bipolar disorder or active major depression History of alcohol or psychotropic substance abuse Pre-existing intellectual disability that precludes neuropsychological evaluation

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    OA-enriched Olive Oil

    Participants will consume 55 mL/day of olive oil enriched with oleanolic acid (600 mg/kg) for 12 months, preferably raw and distributed across the three main meals.

    Dietary Supplement: Oleanolic acid-enriched olive oil

  • Experimental
    Pomace Olive Oil

    Participants will consume 55 mL/day of commercial pomace olive oil, which naturally contains oleanolic acid (180 mg/kg) and erythrodiol (670 mg/kg), for 12 months, preferably raw and distributed across the three main meals.

    Dietary Supplement: Pomace olive oil

  • Placebo comparator
    Control Olive Oil

    Participants will consume 55 mL/day of commercial olive oil 0.4°, which has the same fatty acid composition but a very low content of minor bioactive components, for 12 months, preferably raw and distributed across the three main meals.

    Dietary Supplement: Commercial olive oil 0.4 degrees

Interventions

  • Dietary supplementOleanolic acid-enriched olive oil

    Olive oil enriched with oleanolic acid (600 mg/kg), 55 mL/day for 12 months, consumed preferably raw and distributed across the three main meals.

  • Dietary supplementPomace olive oil

    Commercial pomace olive oil, naturally containing oleanolic acid (180 mg/kg) and erythrodiol (670 mg/kg), 55 mL/day for 12 months, consumed preferably raw and distributed across the three main meals.

  • Dietary supplementCommercial olive oil 0.4 degrees

    Commercial olive oil 0.4°, with the same fatty acid composition but a very low content of minor bioactive components, 55 mL/day for 12 months, consumed preferably raw and distributed across the three main meals.

06

What researchers measure

Primary outcomes

  1. Conversion from prodromal Alzheimer's disease to dementia

    Proportion of participants converting to dementia, defined as a change in the Clinical Dementia Rating Global Score (CDR-GS) from 0.5 at baseline to 1 or higher. The CDR-GS ranges from 0 to 3, with higher scores indicating greater dementia severity

    Time frame: Baseline to 12-months

Secondary outcomes

  1. Change in Clinical Dementia Rating Sum of Boxes (CDR-SB)

    CDR-SB total score ranges from 0 to 18, with higher scores indicating more severe cognitive impairment.

    Time frame: Baseline to 12-months

  2. Change in Mini-Mental State Examination (MMSE) score

    MMSE total score ranges from 0 to 30, with higher scores indicating better global cognitive performance

    Time frame: Baseline to 12-months

  3. Change in Mild Behavioral Impairment Checklist (MBI-C) score

    MBI-C assesses behavioral and psychological symptoms; higher scores indicate more severe symptoms

    Time frame: Baseline to 12-months

  4. Change in Functional Activities Questionnaire (FAQ) score

    FAQ total score ranges from 0 to 30, with higher scores indicating greater functional impairment

    Time frame: Baseline to 12-months

Other outcomes

  1. Change in lipid metabolism biomarkers

    Serum concentrations of total triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, apolipoprotein A1 and apolipoprotein B

    Time frame: Baseline, 6 months and 12 months

  2. Change in glucose metabolism and insulin sensitivity biomarkers

    Plasma glucose, insulin, glycated hemoglobin (HbA1c), HOMA-IR index and Quantitative Insulin Sensitivity Check Index (QUICKI)

    Time frame: Baseline, 6 months and 12 months

  3. Change in plasma lipid classes

    Cholesterol esters, triglycerides, diglycerides, free cholesterol, monoglycerides, phospholipids and ceramides determined by HPLC-MS.

    Time frame: Baseline and 12 months

  4. Change in oxidative stress markers

    Reduced and oxidized glutathione (GSH, GSSG), Nrf2 levels, activities of superoxide dismutase, catalase and heme oxygenase-1, reactive oxygen species production and malondialdehyde.

    Time frame: Baseline, 6 months and 12 months

  5. Change in inflammation markers

    NF-kB p65 and proinflammatory cytokines (TNF-alpha and IL-1beta) measured in plasma or serum.

    Time frame: Baseline, 6 months and 12 months

  6. Change in circulating advanced glycation end products and dicarbonyl compounds and parameters related to their metabolism

    Time frame: Baseline, 6 months and 12 months

  7. Change in blood biomarkers of Alzheimer's disease pathology

    Plasma p-tau 217, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and the amyloid beta 42/40 ratio.

    Time frame: Baseline and 12 months

  8. Serum concentrations of oleanolic acid and erythrodiol

    Time frame: Baseline, 6 months and 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying published results will be made available in institutional repositories, in accordance with the data management plan of the project and with international standards for the documentation of clinical study data.

Supporting information: Study protocol, Informed consent form

Time frame: Data will become available after completion of the project and publication of the main results, and will remain accessible for at least five years thereafter.

Access criteria: Requests for access should be submitted to the principal investigator by e-mail, including a description of the proposed research question and analysis plan. Requests will be evaluated by the study investigators. Access to de-identified individual participant data and to the supporting documents will be granted to researchers whose proposal is considered methodologically sound and consistent with the consent given by study participants, subject to a signed data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Jan 2027
Primary completionEst.
Oct 2028
CompletionEst.
Jan 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847944
Lead sponsor
Spanish National Research Council
Collaborators
Valme University Hospital, Universidad de Granada, Maimónides Biomedical Research Institute of Córdoba, Hospital Universitario Reina Sofia de Cordoba, Universidad Pablo de Olavide
Responsible party
Elena M. Yubero-Serrano (Research Scientist, Instituto de la Grasa) — Principal investigator
First posted
Sep 29, 2026
Start date
Jan 2027 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Elena M Yubero-Serrano, PhD.
Contact
elena.yubero@ig.csic.es
+34687848695

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion